GRO Biosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
2ndary - Private
- Investors
-
17
GRO Biosciences General Information
Description
Developer of a protein engineering platform designed to improve the development of protein-based therapies for complex diseases. The company offers a biotechnology platform with engineered protein design, non-standard amino acid integration, and therapeutic development capabilities, enabling biotechnology and pharmaceutical organizations to create protein-based therapies with improved stability, immune response control, and biological function.
Contact Information
Website
www.grobio.comCorporate Office
- 700 Main Street North
- Lab Central
- Cambridge, MA 02139
- United States
Corporate Office
- 700 Main Street North
- Lab Central
- Cambridge, MA 02139
- United States
GRO Biosciences Timeline
GRO Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 11. Later Stage VC (Series B) | 19-Jul-2024 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 01-Sep-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 03-Nov-2021 | Completed | Generating Revenue | |||
| 7. Grant | 15-Sep-2020 | Completed | Generating Revenue | |||
| 6. Seed Round | 13-Mar-2019 | Completed | Generating Revenue | |||
| 5. Grant | 01-Feb-2019 | Completed | Generating Revenue | |||
| 4. Seed Round | 16-Aug-2017 | $2.4M | $2.4M | Completed | Startup | |
| 3. Accelerator/Incubator | 13-Oct-2016 | Completed | Startup |
GRO Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed-1 | 7,138,773 | $0.000010 | 8% | $0.53 | $0.53 | 1x | $0.53 | 2.46% |
| Seed | 5,165,729 | $0.000010 | 8% | $0.46 | $0.46 | 1x | $0.46 | 1.78% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GRO Biosciences Comparisons
Industry
Financing
Details
GRO Biosciences Competitors (88)
One of GRO Biosciences’s 88 competitors is MeiraGTx, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MeiraGTx | Formerly VC-backed | New York, NY | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Therapure Biopharma | Formerly PE-Backed | Mississauga, Canada | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Byondis | Corporation | Nijmegen, Netherlands |
GRO Biosciences Patents
GRO Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025076412-A1 | Modified polypeptides and methods of making and uses thereof | Inactive | 04-Oct-2023 | ||
| WO-2024086738-A2 | Compositions and methods of use for inteins | Inactive | 19-Oct-2022 | ||
| WO-2024086738-A3 | Compositions and methods of use for inteins | Inactive | 19-Oct-2022 | ||
| WO-2024039740-A2 | Polypeptide compositions containing non-standard glycan stub amino acids and methods of making and uses thereof | Inactive | 16-Aug-2022 | ||
| WO-2024039740-A3 | Polypeptide compositions containing non-standard glycan stub amino acids and methods of making and uses thereof | Inactive | 16-Aug-2022 | C07K14/70571 |
GRO Biosciences Signals
GRO Biosciences Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Page One Ventures | Venture Capital | Minority | ||
| Termeer Institute | Accelerator/Incubator | |||
| The Engine | Accelerator/Incubator |
GRO Biosciences FAQs
-
When was GRO Biosciences founded?
GRO Biosciences was founded in 2016.
-
Where is GRO Biosciences headquartered?
GRO Biosciences is headquartered in Cambridge, MA.
-
What is the size of GRO Biosciences?
GRO Biosciences has 35 total employees.
-
What industry is GRO Biosciences in?
GRO Biosciences’s primary industry is Biotechnology.
-
Is GRO Biosciences a private or public company?
GRO Biosciences is a Private company.
-
What is GRO Biosciences’s current revenue?
The current revenue for GRO Biosciences is .
-
How much funding has GRO Biosciences raised over time?
GRO Biosciences has raised $91.4M.
-
Who are GRO Biosciences’s investors?
Access Biotechnology, Atlas Venture, Page One Ventures, Termeer Institute, and The Engine are 5 of 17 investors who have invested in GRO Biosciences.
-
Who are GRO Biosciences’s competitors?
MeiraGTx, Regenxbio, Therapure Biopharma, Genetix Biotherapeutics, and Byondis are some of the 88 competitors of GRO Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process